Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    0.3%
    Check dated 2025-07-12T04:37:52.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.3%
    Check dated 2025-07-05T02:19:55.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.3%
    Check dated 2025-06-27T18:22:40.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.0%
    Check dated 2025-06-13T15:53:55.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-06T09:29:19.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a revision update from v2.16.0 to v2.16.1.
    Difference
    0.4%
    Check dated 2025-05-30T04:29:10.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.